- Home
- CRGX vs EU Comparison
CRGX vs EU Comparison
Compare CRGX & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- EU
- Stock Information
- Founded
- CRGX 2021
- EU 2009
- Country
- CRGX United States
- EU United States
- Employees
- CRGX N/A
- EU N/A
- Industry
- CRGX
- EU Other Metals and Minerals
- Sector
- CRGX
- EU Basic Materials
- Exchange
- CRGX Nasdaq
- EU Nasdaq
- Market Cap
- CRGX 621.4M
- EU 606.1M
- IPO Year
- CRGX 2023
- EU N/A
- Fundamental
- Price
- CRGX $12.39
- EU $3.32
- Analyst Decision
- CRGX Strong Buy
- EU Strong Buy
- Analyst Count
- CRGX 6
- EU 2
- Target Price
- CRGX $31.80
- EU $6.50
- AVG Volume (30 Days)
- CRGX 287.3K
- EU 1.5M
- Earning Date
- CRGX 11-12-2024
- EU 11-14-2024
- Dividend Yield
- CRGX N/A
- EU N/A
- EPS Growth
- CRGX N/A
- EU N/A
- EPS
- CRGX N/A
- EU N/A
- Revenue
- CRGX N/A
- EU $44,972,063.00
- Revenue This Year
- CRGX N/A
- EU N/A
- Revenue Next Year
- CRGX N/A
- EU $65.28
- P/E Ratio
- CRGX N/A
- EU N/A
- Revenue Growth
- CRGX N/A
- EU N/A
- 52 Week Low
- CRGX $10.91
- EU $3.02
- 52 Week High
- CRGX $33.92
- EU $5.05
- Technical
- Relative Strength Index (RSI)
- CRGX 39.66
- EU 43.40
- Support Level
- CRGX $10.91
- EU $3.26
- Resistance Level
- CRGX $15.75
- EU $3.46
- Average True Range (ATR)
- CRGX 1.20
- EU 0.17
- MACD
- CRGX -0.11
- EU -0.01
- Stochastic Oscillator
- CRGX 30.08
- EU 14.20
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's material properties and projects are the Rosita Project located in Texas, the Alta Mesa Uranium project in Texas, the Crownpoint and Hosta Butte Uranium Project located in New Mexico, the Dewey Burdock Project located in South Dakota, and the Gas Hills Project located in Wyoming.